Over the past three weeks, ABBV has shot up from $215 to $250 after the European Commission approved the drug SKYRIZI for pediatric patients with mild to severe plaque psoriasis. Read More

Antero closed two transactions during Q1 that should be immediately accretive to its financial metrics. Read More

My PF Pro stock screener feels so strongly about the prospects for Eastman Chemical (NYSE: EMN) that I am adding it to our Options Portfolio so that I can add a call option trade to this position. If you already… Read More

There is nothing wrong with the company or its strategy. However, there may be something wrong with the valuation that Wall Street is assigning to BROS given its heavy debt load accumulated as part of its acquisition spree. Read More

The semiconductor stock buying frenzy appears to be losing steam and my PF Pro screener believes this stock still has a lot further to drop. Read More

Our call options for these four positions have a combined return on investment of more than 1,000 percent, so I'm closing them out now before Wall Street decides it's time to go back into a risk-off mode. Read More

This trade is a bet that the buying spree in semiconductor stocks will abate as soon as the Strait of Hormuz reopens and Wall Street resumes its rotation into small cap stocks. Read More

Falling jet fuel prices have airline stocks on the rise, so I'm closing out this position for a 164 percent gain in just two weeks. Read More

I don’t expect AT&T to outperform its guidance for this year, but I think Wall Street will be willing to pay a higher multiple for its earnings once the war in Iran is over. Read More